Research ExplorerPublicationsImproved relapse-free survival after autologous stem cell tr...

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study

Standard

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. / de Wreede, Liesbeth C; Watson, Maggie; van Os, Marleen; Milligan, Donald; van Gelder, Michel; Michallet, Mauricette; Dreger, Peter; Dearden, Claire E; Homewood, Janis; Dupuis, Jehan; Leporrier, Michel; Karas, Michal; Corront, Bernadette; Baerlocher, Gabriela M; Herr, Wolfgang; Choquet, Sylvain; Niederwieser, Dietger W; Sutton, Laurent; Kröger, Nicolaus; de Witte, Theo M; Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council, Johannes.

In: AM J HEMATOL, Vol. 89, No. 2, 01.02.2014, p. 174-80.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

de Wreede, LC, Watson, M, van Os, M, Milligan, D, van Gelder, M, Michallet, M, Dreger, P, Dearden, CE, Homewood, J, Dupuis, J, Leporrier, M, Karas, M, Corront, B, Baerlocher, GM, Herr, W, Choquet, S, Niederwieser, DW, Sutton, L, Kröger, N, de Witte, TM & Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council, J 2014, 'Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study', AM J HEMATOL, vol. 89, no. 2, pp. 174-80. https://doi.org/10.1002/ajh.23610

APA

de Wreede, L. C., Watson, M., van Os, M., Milligan, D., van Gelder, M., Michallet, M., Dreger, P., Dearden, C. E., Homewood, J., Dupuis, J., Leporrier, M., Karas, M., Corront, B., Baerlocher, G. M., Herr, W., Choquet, S., Niederwieser, D. W., Sutton, L., Kröger, N., ... Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council, J. (2014). Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. AM J HEMATOL, 89(2), 174-80. https://doi.org/10.1002/ajh.23610

Vancouver

de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M et al. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. AM J HEMATOL. 2014 Feb 1;89(2):174-80. https://doi.org/10.1002/ajh.23610

Bibtex

@article{5c7648f37fc347bd95316b4c68718446,
title = "Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study",
abstract = "In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on QoL. In the primary analysis, we demonstrate an adverse impact of ASCT on QoL which was largest at 4 months and continued throughout the first year after randomization. Further, we demonstrated a sustained adverse impact of relapse on QoL which worsened over time. Despite better disease control by ASCT the side effects thus turned the net effect towards inferior QoL in the first year and comparable QoL in the following 2 years after randomization. This study emphasizes the importance of information concerning QoL impacts when patients are counseled about treatments aimed at improving RFS in the absence of a survival benefit.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Quality of Life, Questionnaires, Recurrence, Transplantation Conditioning, Transplantation, Autologous",
author = "{de Wreede}, {Liesbeth C} and Maggie Watson and {van Os}, Marleen and Donald Milligan and {van Gelder}, Michel and Mauricette Michallet and Peter Dreger and Dearden, {Claire E} and Janis Homewood and Jehan Dupuis and Michel Leporrier and Michal Karas and Bernadette Corront and Baerlocher, {Gabriela M} and Wolfgang Herr and Sylvain Choquet and Niederwieser, {Dietger W} and Laurent Sutton and Nicolaus Kr{\"o}ger and {de Witte}, {Theo M} and {Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council}, Johannes",
note = "Copyright {\textcopyright} 2013 Wiley Periodicals, Inc.",
year = "2014",
month = feb,
day = "1",
doi = "10.1002/ajh.23610",
language = "English",
volume = "89",
pages = "174--80",
journal = "AM J HEMATOL",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study

AU - de Wreede, Liesbeth C

AU - Watson, Maggie

AU - van Os, Marleen

AU - Milligan, Donald

AU - van Gelder, Michel

AU - Michallet, Mauricette

AU - Dreger, Peter

AU - Dearden, Claire E

AU - Homewood, Janis

AU - Dupuis, Jehan

AU - Leporrier, Michel

AU - Karas, Michal

AU - Corront, Bernadette

AU - Baerlocher, Gabriela M

AU - Herr, Wolfgang

AU - Choquet, Sylvain

AU - Niederwieser, Dietger W

AU - Sutton, Laurent

AU - Kröger, Nicolaus

AU - de Witte, Theo M

AU - Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council, Johannes

N1 - Copyright © 2013 Wiley Periodicals, Inc.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on QoL. In the primary analysis, we demonstrate an adverse impact of ASCT on QoL which was largest at 4 months and continued throughout the first year after randomization. Further, we demonstrated a sustained adverse impact of relapse on QoL which worsened over time. Despite better disease control by ASCT the side effects thus turned the net effect towards inferior QoL in the first year and comparable QoL in the following 2 years after randomization. This study emphasizes the importance of information concerning QoL impacts when patients are counseled about treatments aimed at improving RFS in the absence of a survival benefit.

AB - In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on QoL. In the primary analysis, we demonstrate an adverse impact of ASCT on QoL which was largest at 4 months and continued throughout the first year after randomization. Further, we demonstrated a sustained adverse impact of relapse on QoL which worsened over time. Despite better disease control by ASCT the side effects thus turned the net effect towards inferior QoL in the first year and comparable QoL in the following 2 years after randomization. This study emphasizes the importance of information concerning QoL impacts when patients are counseled about treatments aimed at improving RFS in the absence of a survival benefit.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Quality of Life

KW - Questionnaires

KW - Recurrence

KW - Transplantation Conditioning

KW - Transplantation, Autologous

U2 - 10.1002/ajh.23610

DO - 10.1002/ajh.23610

M3 - SCORING: Journal article

C2 - 24123244

VL - 89

SP - 174

EP - 180

JO - AM J HEMATOL

JF - AM J HEMATOL

SN - 0361-8609

IS - 2

ER -